SAFETY DATA SHEET

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture	IMURAN TABLETS
Registration number	-
Synonyms	IMURAN 25 MG TABLETS * IMURAN 50 MG TABLETS * IMUREK FILMTABLETTEN * IMUREL TABLETS * AZATHIOPRINE, FORMULATED PRODUCT
Issue date	06-November-2014
Version number	13
Revision date	06-November-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses	Medicinal Product. This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.
Uses advised against	No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES::
UK In-country toll call: +(44)-870-8200418
International toll call: +1 703 527 3887
available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.3. Other hazards Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
AZATHIOPRINE	31.4 - < 31.8	446-86-6 207-175-4	-	-	
Classification: **DSD:** Carc. Cat. 1;R45, Muta. Cat. 1;R46, Muta. Cat. 2;R46, Repr. Cat. 2;R61, Xn;R22-48, Xi;R36-37-38, R43 **CLP:** Acute Tox. 4;H302, Skin Irrit. 2;H315, Skin Sens. 1;H317, Eye Irrit. 2;H319, STOT SE 3;H335, Muta. 1B;H340, Carc. 1A;H350, Repr. 1B;H360, STOT RE 1;H372					
Starch	10 - < 20	9005-25-8 232-679-6	-	-	
Classification: **DSD:** - **CLP:** -					
HYDROXYPROPYL METHYL CELLULOSE	1 - < 3	9004-65-3 -	-	-	
Classification: **DSD:** - **CLP:** -					
MAGNESIUM STEARATE	< 1	557-04-0 209-150-3	-	-	
Classification: **DSD:** - **CLP:** -					
Titanium dioxide	< 0.2	13463-67-7 236-675-5	-	-	
Classification: **DSD:** - **CLP:** -					
Other components below reportable levels	40 - < 50				

List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.
DSD: Directive 67/548/EEC.
M: M-factor
vPvB: very persistent and very bioaccumulative substance.
PBT: persistent, bioaccumulative and toxic substance.
#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

4.1. Description of first aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if symptoms develop or persist. Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control centre immediately. Do not induce vomiting without advice from poison control center.

4.2. Most important symptoms and effects, both acute and delayed Accidental exposure or contact might produce: symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), nausea, vomiting, increased susceptibility to infection.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing media Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing media None known.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures Move containers from fire area if you can do so without risk.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

6.2. Environmental precautions Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water.

6.4. Reference to other sections For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

SECTION 7: Handling and storage

7.1. Precautions for safe handling Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. Do not taste or swallow. When using, do not eat, drink or smoke. Pregnant or breastfeeding women must not handle this product. Should be handled in closed systems, if possible. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Observe good industrial hygiene practices.

7.2. Conditions for safe storage, including any incompatibilities Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

7.3. Specific end use(s) Medicinal Product.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK

Components	Type	Value	Note
AZATHIOPRINE (CAS 446-86-6)	8 HR TWA	3 mcg/m3	
	OHC	4	Carcinogen
		4	Reproductive hazard
		4	SKIN SENSITISER
HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)	OHC	1	

Ireland. Occupational Exposure Limits

Components	Type	Value	Form
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	
Starch (CAS 9005-25-8)	TWA	4 mg/m3	Respirable dust.
		10 mg/m3	Total inhalable dust.

Ireland. Occupational Exposure Limits

Components	Type	Value	Form
Titanium dioxide (CAS 13463-67-7)	TWA	4 mg/m3	Respirable dust.
		10 mg/m3	Total inhalable dust.

Biological limit values No biological exposure limits noted for the ingredient(s).

Recommended monitoring procedures Follow standard monitoring procedures.

Derived no-effect level (DNEL) Not available.

Predicted no effect concentrations (PNECs) Not available.

Exposure guidelines

8.2. Exposure controls

Appropriate engineering controls General ventilation normally adequate. An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment.

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

Eye/face protection If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166). Not normally needed.

Skin protection

- Hand protection For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time). Not normally needed.

- Other Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for splashes, EN ISO 13982 for dust). Not normally needed.

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg. EN 14387). No personal respiratory protective equipment normally required.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional.

Environmental exposure controls

Hazard guidance and control recommendations Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid.

Form Tablet.

Colour Not available.

Odour Not available.

Odour threshold Not available.

pH Not available.

Melting point/freezing point Not available.

Initial boiling point and boiling range Not available.

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%) Not available.

Flammability limit - upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Solubility (other)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Explosive properties	Not available.
Oxidizing properties	Not available.
9.2. Other information	No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
10.2. Chemical stability	Material is stable under normal conditions.
10.3. Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
10.4. Conditions to avoid	Contact with incompatible materials.
10.5. Incompatible materials	Strong oxidising agents.
10.6. Hazardous decomposition products	None known. Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

SECTION 11: Toxicological information

General information	Occupational exposure to the substance or mixture may cause adverse effects.
Information on likely routes of exposure	
Inhalation	Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Health injuries are not known or expected under normal use.
Eye contact	Health injuries are not known or expected under normal use.
Ingestion	Health injuries are not known or expected under normal use. May be harmful if swallowed.
Symptoms	Accidental exposure or contact might produce: nausea, vomiting, symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), increased susceptibility to infection.

11.1. Information on toxicological effects

Acute toxicity	Expected to be a low hazard for usual industrial or commercial handling by trained personnel. May be harmful if swallowed.

Components	Species	Test results
AZATHIOPRINE (CAS 446-86-6)		
Acute		
Oral		
LD50	Rat	400 mg/kg
HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)		
Acute		
Oral		
LD50	Rat	> 2000 mg/kg
MAGNESIUM STEARATE (CAS 557-04-0)		
Acute		
Oral		
LD50	Rat	> 2000 mg/kg
Titanium dioxide (CAS 13463-67-7)		
Acute		
Inhalation		
LC50	Rat	6820 mcg/m3

Components	Species	Test results
Oral		
LD50	Rat	> 24 g/kg
Chronic		
Inhalation		
LOEC	Rat	8.6 mg/m3, 1 years TiO2 accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.
NOAEC	Rat	250 mg/m3, 2 years Highest dose 5 mg/m3, 24 months
Subacute		
Inhalation		
LOEL	Rat	0.1 - 35 mg/m3, 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid.
NOAEC	Guinea pig	26 mg/m3, 3 weeks No evidence of significant inflammation in respiratory tract.
Oral		
NOAEL	Rat	100000 ppm, 14 Day Dietary study, highest dose tested.
Subchronic		
Inhalation		
LOEC	Rat	3.2 - 20 mg/m3, 8 min Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin

TITANIUM DIOXIDE	0, Literature data Result: Non-irritant Species: Guinea pig 0, Literature data Result: Non-irritant Species: Human Acute dermal irritation; OECD 404, Literature data Result: Non-irritant Species: Rabbit

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE	0

Serious eye damage/eye irritation Health injuries are not known or expected under normal use.

Eye

TITANIUM DIOXIDE	OECD 405, Literature data Result: Mild irritant Species: Rabbit

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE	4 Recovery Period: 2 days

Respiratory sensitisation No studies have been conducted.

Skin sensitisation May cause an allergic skin reaction.

Maximisation assay (Magnusson and Kligman)

HYDROXYPROPYL METHYL CELLULOSE	Result: negative Species: Guinea pig

Sensitisation

TITANIUM DIOXIDE	5 % Optimisation Test, Literature data - Vehicle: petrolatum Result: negative Species: Guinea pig Test Duration: 48 hour exposure
AZATHIOPRINE	Occupational exposure, Literature data Result: Low incidence of contact hypersensitivity. Species: Human

Sensitisation

TITANIUM DIOXIDE	Patch test, Literature data Result: negative Species: Human

Germ cell mutagenicity May cause genetic defects.

Mutagenicity

AZATHIOPRINE	Ames Assay, GLP assay; Literature data Result: positive
TITANIUM DIOXIDE	Ames, Literature data Result: negative Micronucleus Assay in vitro, CHO cells, Literature data Result: negative Micronucleus Assay in vitro, cultured human peripheral lymphocytes, Literature data Result: positive
AZATHIOPRINE	Micronucleus Test, GLP assay; Literature data Result: positive
TITANIUM DIOXIDE	Syrian Hamster Embryo (SHE) cell transformation assay Result: negative WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell lymphoblastoid, Literature data Result: positive

Carcinogenicity Contains a material (Azathioprine) classified as a carcinogen by external agencies.

TITANIUM DIOXIDE	0.5 mg/m3, Literature data Result: negative Species: Rat Test Duration: 24 months 0.72 - 14.8 mg/m3, Literature data Result: negative Species: Mouse 10 - 250 mg/m3, Dietary study - Literature data. Result: Inflammation at all doses with alveolar/bronchiolar adenoma at the highest concentration. Species: Rat Test Duration: 24 months 25000 - 50000 ppm, Dietary study Result: negative Species: Mouse 25000 - 50000 ppm, Dietary study - Literature data. Result: negative Species: Rat 7.2 - 14.8 mg/m3, Literature data Result: Lung tumour Species: Rat Test Duration: 24 months
AZATHIOPRINE	Literature search Result: positive

IARC Monographs. Overall Evaluation of Carcinogenicity

AZATHIOPRINE (CAS 446-86-6)	1 Carcinogenic to humans.
Titanium dioxide (CAS 13463-67-7)	2B Possibly carcinogenic to humans.

Reproductive toxicity May damage fertility or the unborn child.

Reproductivity

AZATHIOPRINE	Literature search Result: Positive for teratogenicity, fertiltiy effects and may affect the quality of breast milk.

Specific target organ toxicity - single exposure Not available.

Specific target organ toxicity - repeated exposure Causes damage to organs through prolonged or repeated exposure.

AZATHIOPRINE	Literature search Organ: Immune system, Bone marrow and formation of blood cells, Liver, Kidney

Aspiration hazard Not likely, due to the form of the product.

Mixture versus substance information No information available.

Other information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.

SECTION 12: Ecological information

12.1. Toxicity Not expected to be harmful to aquatic organisms.

Components		Species	Test results
AZATHIOPRINE (CAS 446-86-6)			
Acute			
	IC50	Activated sludge	> 1000 mg/l, 3 hours
Aquatic			
Acute			
Algae	EC50	Green algae (Scenedesmus subspicatus)	> 100 mg/l, 72 hours Static test
	NOEC	Green algae (Scenedesmus subspicatus)	100 mg/l, 72 hours Static test
Crustacea	EC50	Water flea (Daphnia magna)	> 100 mg/l, 48 hours Static test
	NOEC	Water flea (Daphnia magna)	> 100 mg/l, 48 hours Static test
HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)			
Aquatic			
Acute			
Fish	EC50	Fish	> 100 mg/l, 96 hours
MAGNESIUM STEARATE (CAS 557-04-0)			
Aquatic			
Acute			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
Titanium dioxide (CAS 13463-67-7)			
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	> 1000 mg/l, 48 hours Static test

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE	17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE	210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

AZATHIOPRINE	4 %, 28 days Modified Zahn-Wellens, DOC removal., Activated sludge 4 %, 28 days Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge
MAGNESIUM STEARATE	77 %, 28 days BOD

Percent degradation (Aerobic biodegradation-ready)

AZATHIOPRINE	11 %, 28 days Modified Sturm test.
MAGNESIUM STEARATE	95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE	50 %, 13 days

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

AZATHIOPRINE	-0.787
HYDROXYPROPYL METHYL CELLULOSE	-5

Bioconcentration factor (BCF)

HYDROXYPROPYL METHYL CELLULOSE	3.2 Estimated
MAGNESIUM STEARATE	> 9999 Estimated

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE	5.86 Estimated

Mobility in general

Volatility

Henry's law

AZATHIOPRINE	0 atm m^3/mol, 25 C Estimated
HYDROXYPROPYL METHYL CELLULOSE	0 atm m3/mol Estimated

12.5. Results of PBT and vPvB assessment Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

EU waste code The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable regulations.

Special precautions Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations	The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.
National regulations	Young people under 18 years old are not allowed to work with this product according to the EU Directive 94/33/EC on the protection of young people at work. Follow national regulation for work with chemical agents.
15.2. Chemical safety assessment	No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations	Not available.
References	GSK Hazard Determination
Information on evaluation method leading to the classification of mixture	The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.
Full text of any statements or R-phrases and H-statements under Sections 2 to 15	R22 Harmful if swallowed. R36 Irritating to eyes. R37 Irritating to respiratory system. R38 Irritating to skin. R43 May cause sensitization by skin contact. R45 May cause cancer. R46 May cause heritable genetic damage. R48 Danger of serious damage to health by prolonged exposure. R61 May cause harm to the unborn child. H302 Harmful if swallowed. H315 Causes skin irritation. H317 May cause an allergic skin reaction. H319 Causes serious eye irritation. H335 May cause respiratory irritation. H340 May cause genetic defects. H350 May cause cancer. H360 May damage fertility or the unborn child. H372 Causes damage to organs through prolonged or repeated exposure.
Revision information	Product and Company Identification: Product and Company Identification Composition / Information on Ingredients: Ingredients Exposure Controls / Personal Protection: Physical & Chemical Properties: Ecological Information: Ecotoxicity Transport Information: Agency Name and Packaging Type/Transport Mode Selection Regulatory Information: Risk Phrases - Class. GHS: Classification
Training information	Follow training instructions when handling this material.
Disclaimer	The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.